

## MONTHLY INTELLIGENCE | UPCOMING EVENTS

**CLIENT INTERVIEW: ADAM KEENEY, CEO OF NODTHERA AND FORMER GLOBAL HEAD OF BUSINESS DEVELOPMENT AT SANOFI GENZYME, TALKS TO CONSILIUM ABOUT THE CHALLENGES AND OPPORTUNITIES OF JUMPING FROM A CAREER IN BIG PHARMA TO MANNING A SMALL BIOTECH COMPANY****Q. What is the appeal of working with a small biotech following a career in big pharma?**

Working in Pharma provided me with a wealth of opportunities to learn our industry, both from an R&D perspective but also through a commercial, executive management and strategy lens. Leading Business Development activities at J&J, and then more recently at Sanofi Genzyme, allowed me to interact and learn from multiple functions across the value chain from drug discovery, IP and manufacturing to translational medicine, clinical development and regulatory. I have had the opportunity to work with some great teams with deep expertise and benefited from the diversity of those experiences. I now welcome the opportunity to apply those learnings to driving projects in a nimble, agile biotech company.

**Q. What have been the initial challenges of joining a small company?**

Joining NodThera, which is focused on next generation NLRP3 inflammasome inhibitors for diseases driven by chronic inflammation and that recently raised a \$40m Series A backed by Sofinova Partners and 5AM Ventures, has been a wonderful experience — so far! We are fortunate to have a great team and supportive Board. Even though I had less than two weeks to prepare for my first Board meeting, the support of the team meant it was a productive discussion where we were able to gain alignment quickly. I am currently enjoying the challenge of setting up an office in Boston and also continuing to recruit a world class team, but those are nice problems to have...

**Q. What are the challenges in moving from rare diseases to working in the inflammasome space, where there is potential to target multiple chronic inflammation indications?**

The inflammasome is a relatively new area of

science, with novel discoveries and opportunities arising weekly. However, as a small company, we will need to choose carefully where to focus and build deep expertise. This will take into account a number of factors, including the robustness of the science in a particular indication, the translational path towards the clinic and the overall level of pharma interest and commercial viability. We have begun this work and are currently considering Fibrosis and Neurology as initial areas of focus as the role of the inflammasome in these sets of diseases is well validated, with the path to the clinic clear and a significant unmet medical need to provide value if we are successful.

**Q. What cultural differences have you picked up on between working in the UK and US healthcare?**

Coming from the UK myself, joining NodThera has been like coming home. Cambridge, UK has a long pharma history which provides access to fantastic talent in an emerging biotech scene. Of course, also being based in Boston, MA provides us access to world class collaborators, a deep talent pool and access to investors and future pharma partners. So we are able to take advantage of the best of both locations. I do have to say though, that the UK offices consumes significantly more (Yorkshire) tea than our entire current US operation!

**Q. From your point of view, what is changing in the sector? What still needs to change?**

It is clear that great science and compelling clinical data is not sufficient in the new world of pharma. We also have to clearly articulate the value proposition to key stakeholders: patients, prescribers and, even more importantly, payers. How do our new medicines beat standard of care, how do they truly add value to the system and, overall, how are they going to be cost effective is now a key consideration in the earliest stages of drug development.

**MONTHLY INTELLIGENCE****MEDIA MOVES**

- **Denise Roland**, Wall Street Journal, has returned from maternity leave
- **Bruno Dubrelle** has joined Reuters as Financial Headlines News Reporter, covering France and Benelux

**BANKING MOVES**

- **Dr William Palmer-Brown** has joined the Panmure Gordon corporate team

**ANALYST MOVES**

- **Edward Thomason** has joined N+1 Singer as a healthcare analyst





## THIS MONTH'S MOVERS AND SHAKERS

- Oncimmune appointed **Dr Cheung To** as Non-Executive Director
- Sensyne Health appointed **Professor Lionel Tarassenko** as Non-Executive Director and Director of R&D
- Ergomed appointed **Michael Spiteri** as Non-Executive Director
- Novo Nordisk appointed **Ludovic Helfgott** as Executive VP of its biopharm unit effective April 3, 2019
- Malin appointed **Ian Curley** as Executive Chairman on an interim basis
- Merck appointed **Nick Haining** as VP of Oncology
- Perrigo appointed **Murray Kessler** as CEO
- F-star appointed **Dr Eliot Forster** as CEO
- Pfizer appointed **Albert Bourla** as CEO and **Ian Read** as Executive Chairman
- Nimbus Therapeutics promoted CFO **Jeb Keiper** to President and CEO
- Synlogic appointed **Aoife Brennan** as CEO
- Second Genome appointed **Karim Dabbagh** as President and CEO
- Carrick Therapeutics appointed **Dr George Golumbeski** as Chairman
- Hummingbird Diagnostics appointed **Jörg Debatin** as Chairman of its Supervisory Board
- CASI Pharmaceuticals appointed **George Chi** as CFO
- Rechiparm AB appointed **Tobias Häggglöv** as CFO
- Curis promoted COO **James Dentzer** to President and CEO, following the departure of CEO **Ali Fattaey**
- Selecta Biosciences appointed **Carsten Brunn** as President and CEO
- NodThera appointed **Awdam Keeney** as President and CEO
- BioTime appointed **Brian Culley** as CEO
- Virion Biotherapeutics appointed **Vanessa King** as CEO and **Isabel Najera** as CSO
- Portola Pharmaceuticals appointed **Scott Garland** as President and CEO
- Melinta Therapeutics appointed **Peter Milligan** as CFO
- The Pharmaceutical Care Management Association appointed **JC Scott** as President and CEO
- Medacta International promoted EVP **Francesco Siccardi** to CEO
- Promethera Biosciences promoted **Mutsuki Takano** to CFO



## HIGHLIGHTED FUNDRAISING ACTIVITY FROM SEPTEMBER TO OCTOBER 2018

COMPANY NAME	AMOUNT RAISED	TYPE OF FUNDRAISE	COUNTRY	DATE
<b>PUBLIC COMPANY FINANCINGS</b>				
<b>CRISPR Therapeutics</b>	\$200 million	Follow-on	US	21-Sep-18
<b>Viking Therapeutics Inc.</b>	\$175.8 million	Follow-on	US	21-Sep-18
<b>Fate Therapeutics Inc.</b>	\$125 million	Follow-on	US	21-Sep-18
<b>Molecular Templates Inc.</b>	\$45.1 million	Follow-on	US	21-Sep-18
<b>Synairgen plc</b>	£2.9 million	Placing	UK	25-Sep-18
<b>Entasis Therapeutics Holdings Inc.</b>	\$75 million	IPO	US	26-Sep-18
<b>AnaptysBio Inc.</b>	\$207.8 million	Follow-on	US	26-Sep-18
<b>Arvinas Inc.</b>	\$120 million	IPO	US	27-Sep-18
<b>Sutro Biopharma Inc.</b>	\$85 million	IPO	US	27-Sep-18
<b>Urovant Sciences Ltd.</b>	\$140 million	IPO	US	27-Sep-18
<b>Akari Therapeutics plc</b>	\$20 million	Securities Purchase	US	27-Sep-18
<b>Gritstone Oncology Inc.</b>	\$100 million	IPO	US	28-Sep-18
<b>Aldeyra Therapeutics Inc.</b>	\$72.2 million	Follow-on	US	28-Sep-18
<b>Nightstar Therapeutics plc</b>	\$72 million	Follow-on	US	28-Sep-18
<b>Curetis N.V.</b>	€20 million	Convertible Notes	Netherlands	2-Oct-18
<b>GW Pharmaceuticals plc</b>	\$300 million	Follow-on	US	3-Oct-18
<b>Epizyme Inc.</b>	\$75 million	Follow-on	US	3-Oct-18
<b>Kala Pharmaceuticals Inc.</b>	\$61.9 million	Follow-on	US	3-Oct-18
<b>Allogene Therapeutics Inc.</b>	\$324 million	IPO	US	11-Oct-18
<b>Audentes Therapeutics Inc.</b>	\$150.8 million	Follow-on	US	11-Oct-18
<b>Iovance Biotherapeutics</b>	\$219.3 million	Follow-on	US	12-Oct-18
<b>PRIVATE COMPANY FINANCINGS</b>				
<b>Altheia Science Srl</b>	\$11 million	Series A	Italy	24-Sep-18
<b>PervasID</b>	£1.6 million	Series A	UK	25-Sep-18
<b>Morphic Therapeutic</b>	\$80 million	Series B	US	25-Sep-18
<b>Lyra Therapeutics Inc.</b>	\$29.5 million	Series B	US	26-Sep-18
<b>Akrevia Therapeutics LLC</b>	\$30 million	Series A	US	27-Sep-18
<b>A-Mansia Biotech S.A.</b>	€18 million	Series A	Netherlands	27-Sep-18
<b>KSQ Therapeutics Inc.</b>	\$80 million	Series C	US	28-Sep-18
<b>VelosBio Inc.</b>	\$58 million	Series A	US	1-Oct-18
<b>Modis Therapeutics Inc.</b>	\$30 million	Series A	US	1-Oct-18
<b>Sitryx Therapeutics Ltd.</b>	\$30 million	Series A	UK	8-Oct-18
<b>Glympse Bio Inc.</b>	\$22 million	Series A	US	9-Oct-18
<b>Gotham Therapeutics</b>	\$54 million	Series A	US	10-Oct-18
<b>Sequana Medical N.V.</b>	€8.5 million	Financing	Belgium	15-Oct-18
<b>CuraSen Therapeutics Inc.</b>	\$54.5 million	Series A	US	17-Oct-18
<b>TP Therapeutics Inc.</b>	\$80 million	Mezzanine round	US	19-Oct-18
<b>Glycotest Inc.</b>	\$10 million	Series A	US	22-Oct-18



# INVESTOR CONFERENCE EVENT CALENDAR

## 2018

### NOVEMBER

- FT Global Pharmaceutical and Biotechnology Conference 2018**, London (5-6 November)
- BIO-Europe 2018**, Copenhagen (5-7 November)
- Credit Suisse Annual Healthcare Conference**, Scottsdale (5-7 November)
- Biotech and Money Inv€stival Showcase**, London (13 November)
- Consilium Strategic Communications Annual Healthcare Conference**, London (13 November)
- Boston Biotech Europe CEO**, London (13-14 November)
- Stifel Nicolaus Weisel Healthcare Conference 2018**, New York (13-14 November)
- Jefferies Healthcare Conference**, London (14-15 November)
- Canaccord Genuity Medical Technology and Diagnostics Forum**, New York (15 November)
- Evercore ISI Healthcare Conference**, Boston (27-29 November)
- Piper Jaffray Annual Healthcare Conference**, New York (27-29 November)
- Forbes Healthcare Summit**, New York (28-29 November)

### DECEMBER

- Berenberg Bank Annual European Conference**, Surrey (3-6 December)
- Citibank Global Healthcare Conference**, New York (5-6 December)

## 2019

### JANUARY

- BioTech Showcase 2019**, San Francisco (7-9 January)
- JP Morgan Annual Healthcare Conference**, San Francisco (7-10 January)
- Future of Healthcare Investor Forum**, London (TBD)
- Annual Needham Growth Conference**, New York (TBD)

### FEBRUARY

- Annual BIO CEO & Investor Conference**, New York (11-12 February)
- RBC Capital Markets 2019 Healthcare Conference**, New York (20-21 February)
- Annual JMP Securities Technology Research Conference**, San Francisco (25-26 February)
- Annual European Life Science CEO Forum & Exhibition**, Zurich (TBD)
- Leerink Partners Global Healthcare Conference 2019**, New York (27 February-1 March)
- ASCO-SITC Clinical Immuno-Oncology Symposium**, San Francisco (28 February-2 March)
- Morgan Stanley European MedTech & Services Conference**, London (TBD)

### MARCH

- Credit Suisse Healthcare One-on-One Conference**, London (5-6 March)
- Roth Capital Partners Annual Conference**, Orange County (10-12 March)
- Cowen & Co. Annual Health Care Conference**, Boston (11-13 March)
- Barclays Capital Healthcare Conference**, Miami (12-14 March)
- BIO-Europe Spring**, Vienna (25-27 March)
- Raymond James Annual Institutional Investors Conference**, Orlando (TBD)
- Boston BioTech BD Conference**, Boston (TBD)
- Oppenheimer & Co. Annual Healthcare Conference**, New York (TBD)
- BioCentury Future Leaders in the Biotech Industry**, New York (TBD)
- KBC Securities Healthcare Conference**, Brussels (TBD)
- Needham & Co. Annual Healthcare Conference**, New York (TBD)

### APRIL

- Needham & Co. Annual Healthcare Conference**, New York (9-10 April)
- HC Wainwright Monaco Global Biotechnology Conference**, Monaco (TBD)
- ARM Cell & Gene Therapy Investor Day**, New York (TBD)
- Kempen & Co Life Sciences Conference**, Amsterdam (TBD)
- BioTrinity 2019**, London (29 April-1 May)
- ChinaBio Partnering Forum**, Suzhou (TBD)

CONSILIUM IS THE OFFICIAL PR AGENCY FOR

## THE ECONOMIST EVENTS WAR ON CANCER 2018

The Economist EVENTS

### WAR ON CANCER EUROPE

The technological  
revolution and the  
future of patient  
engagement

November 20th  
2018

London

25% off with code CONSILIUM/DC

Register today

To book a place with an exclusive Consilium 25% discount rate, please use the code above or contact a member of Consilium's healthcare team: [WarOnCancer2018@consilium-comms.com](mailto:WarOnCancer2018@consilium-comms.com)

# CONSILIUM STRATEGIC COMMUNICATIONS, BERENBERG, COOLEY AND WESTWICKE PARTNERS 2018 ANNUAL HEALTHCARE CONFERENCE

Consilium Strategic Communications is looking forward to hosting its Annual Healthcare Conference, in association with Berenberg, Cooley and Westwicke Partners. The invitation-only, half-day event will take place on the afternoon of **13 November 2018**, at **De Vere Grand Connaught Rooms, 61-65 Great Queen St, London WC2B 5DA**, starting with lunch at 12pm and concluding with drinks and networking from 5pm.

Our conference, now an established fixture on the healthcare conference circuit, assembles high-quality speakers from across the international healthcare sector and investment community for a state-of-the-nation sector review. Our panels will explore the new and diverse forms of fundraising across the sector, discuss how the infrastructure of the biopharma industry is coping with the advent of advanced therapies, and examine the progress of artificial intelligence from blue-sky thinking to the next 'big thing'. We'll conclude with a fireside chat with Scrip's content chief Mike Ward and former Teva global R&D chief Michael Hayden.

## AGENDA:

- 12:00 - 13:00** LUNCH
- 13:00 - 13:15** WELCOME AND INTRODUCTIONS
- 13:15 - 13:30** KEYNOTE - TOM LYNCH, EVOFEM BIOSCIENCES
- 13:30 - 14:15** PANEL 1 - VENTURE FORTH
- 14:15 - 15:00** PANEL 2 - ADVANCED THERAPIES
- 15:00 - 15:30** BREAK
- 15:30 - 16:15** PANEL 3 - AI
- 16:15 - 17:00** FIRESIDE CHAT BETWEEN MIKE WARD, SCRIP, AND MICHAEL HAYDEN,  
FORMER TEVA GLOBAL R&D CSO
- 17:00** NETWORKING AND DRINKS

## CONFIRMED PANELLISTS AND SPEAKERS INCLUDE:

**James Noble**, Adaptimmune; **Naveed Siddiqi**, Andera Partners; **Eva-Lotta Allan**, C4X Discovery; **Clive Dix**, C4X Discovery; **John Brown**, Cell Therapy Catapult; **Victor Christou**, Cambridge Innovation Capital; **Tom Lynch**, Evofem Biosciences; **Shane de Bhruin Smith**, Hargreave Hale; **Mike Ward**, SCRIP; **Mike Townend**, IP Group; **Jean Pol Detiffe**, OncoDNA; **Annalisa Jenkins**, Cell Medica; **Bharatt Chowrira**, PureTech; **Paul Drayson**, Sensyne Health; **Tom Burt**, Sofinnova Partners; **Chris Hollowood**, Syncona Limited; **Michael Hayden**, ex-Teva

If you are interested in attending, please contact Liza Carr, Rachael Alisedaghat or Harpreet Viridi: [admincsc@consilium-comms.com](mailto:admincsc@consilium-comms.com)



Webcast by:

